Lazard Asset Management LLC raised its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Get Rating) by 110.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,043 shares of the company’s stock after buying an additional 2,126 shares during the period. Lazard Asset Management LLC’s holdings in Amphastar Pharmaceuticals were worth $140,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also recently made changes to their positions in the company. US Bancorp DE lifted its stake in shares of Amphastar Pharmaceuticals by 49.5% in the second quarter. US Bancorp DE now owns 2,023 shares of the company’s stock valued at $70,000 after buying an additional 670 shares in the last quarter. Point72 Hong Kong Ltd bought a new position in shares of Amphastar Pharmaceuticals in the first quarter valued at $74,000. Nisa Investment Advisors LLC lifted its stake in shares of Amphastar Pharmaceuticals by 22.0% in the second quarter. Nisa Investment Advisors LLC now owns 2,550 shares of the company’s stock valued at $89,000 after buying an additional 460 shares in the last quarter. Captrust Financial Advisors lifted its stake in shares of Amphastar Pharmaceuticals by 114.4% in the first quarter. Captrust Financial Advisors now owns 2,770 shares of the company’s stock valued at $99,000 after buying an additional 1,478 shares in the last quarter. Finally, KBC Group NV bought a new position in shares of Amphastar Pharmaceuticals during the second quarter valued at about $111,000. 63.11% of the stock is owned by institutional investors.
Amphastar Pharmaceuticals Stock Performance
NASDAQ AMPH opened at $28.40 on Tuesday. Amphastar Pharmaceuticals, Inc. has a 52-week low of $19.21 and a 52-week high of $44.46. The company has a 50-day simple moving average of $28.99 and a 200 day simple moving average of $32.22. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.75 and a current ratio of 3.76. The company has a market capitalization of $1.37 billion, a PE ratio of 19.06 and a beta of 0.74.
Analysts Set New Price Targets
About Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API.
- Get a free copy of the StockNews.com research report on Amphastar Pharmaceuticals (AMPH)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here’s What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.